Inmed Pharmaceuticals vs Entrada Therapeutics
Entrada Therapeutics is the larger business, with $25.4m of revenue in fiscal 2025 against $4.9m for Inmed Pharmaceuticals (5.1 times as much). Inmed Pharmaceuticals grew faster (7.5% against -87.9%). Inmed Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -34.4% against -565.5%.
| Latest fiscal year | Inmed PharmaceuticalsINM, 2025 | Entrada TherapeuticsTRDA, 2025 |
|---|---|---|
| Revenue | $4.9m | $25.4m |
| Revenue growth | 7.5% | -87.9% |
| Net income | −$1.7m | −$144m |
| Operating margin | — | -621.1% |
| Net margin | -34.4% | -565.5% |
| Return on equity | -15.0% | -39.1% |
| Free cash flow | −$8.1m | −$130m |
| Cash | $10.7m | $90.4m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 6 | 152 |
| Market value | $9.2m | $185m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 49 buys, 0 sales | 17 buys, 44 sales |